glp 1 egfr cut off GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of kidney failure. Adverse events are mostly gastrointestinal Kidney and Cardiovascular Outcomes Among

By considering procedures like tummy tuck and liposuction, Dr

Oral GLP-1s work best when combined with these foundational strategies

STEP-4 trial data demonstrated 14% body weight rebound following Wegovy discontinuation at 68 weeks , establishing clinical justification for long-term GLP-1 therapy that insurers and national health technology bodies are progressively incorporating into obesity management protocols

By binding to GLP-1 receptors, these medications enhance glucose-dependent insulin secretion from pancreatic beta cells, suppress inappropriate glucagon release, slow gastric emptying, and promote satiety through central nervous system pathways